<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
  • Menu
  • crown-logo-symbol-1-400x551

Find it Quickly

Get Started

Select the option that best describes what you are looking for

  • Services
  • Models
  • Scientific Information

Search Here For Services

Click Here to Start Over

Search Here For Models

Click Here to Start Over

Search Here For Scientific Information

Click Here to Start Over

In Vitro

Boost oncology drug discovery with XenoBase®, featuring the largest cell line selection and exclusive 3D organoid models. Benefit from OrganoidXplore™ and OmniScreen™ for rapid, in-depth analysis.

Learn More

In Vivo

Enhance drug development with our validated in vivo models, in vitro/ex vivo assays, and in silico modeling. Tailored solutions to optimize your candidates.

Learn More

Tissue

Experience ISO-certified biobanking quality. Access top biospecimens from a global clinical network, annotated by experts for precise research.

Learn More

Biomarkers and Bioanalysis

Leverage our global labs and 150+ scientists for fast, tailored project execution. Benefit from our expertise, cutting-edge tech, and validated workflows for reliable data outcomes.

Learn More

Data Science and Bioinformatics

Harness your data and discover biomarkers with our top bioinformatics expertise. Maximize data value and gain critical insights to accelerate drug discovery and elevate projects.

Learn More

KRAS

Accelerate innovative cancer treatments with our advanced models and precise drug screening for KRAS mutations, efficiently turning insights into clinical breakthroughs.

Learn More

EGFR

Advance translational pharmacology with our diverse pre-clinical models, robust assays, and data science-driven biomarker analysis, multi-omics, and spatial biology.

Learn More

Drug Resistance

Our suite integrates preclinical solutions, bioanalytical read-outs, and multi-omics to uncover drug resistance markers and expedite discovery with our unique four-step strategy.

Learn More

Patient Tissue

Enhance treatments with our human tumor and mouse models, including xenografts and organoids, for accurate cancer biology representation.

Learn More

Bioinformatics

Apply the most appropriate in silico framework to your pharmacology data or historical datasets to elevate your study design and analysis, and to improve your chances of clinical success.

Learn More

Biomarker Analysis

Integrate advanced statistics into your drug development projects to gain significant biological insight into your therapeutic candidate, with our expert team of bioinformaticians.

Learn More

CRISPR/Cas9

Accelerate your discoveries with our reliable CRISPR solutions. Our global CRISPR licenses cover an integrated drug discovery platform for in vitro and in vivo efficacy studies.

Learn More

Genomics

Rely on our experienced genomics services to deliver high quality, interpretable results using highly sensitive PCR-based, real-time PCR, and NGS technologies and advanced data analytics.

Learn More

In Vitro High Content Imaging

Gain more insights into tumor growth and disease progression by leveraging our 2D and 3D fluorescence optical imaging.

Learn More

Mass Spectrometry-based Proteomics

Next-generation ion mobility mass spectrometry (MS)-based proteomics services available globally to help meet your study needs.

Learn More

Ex Vivo Patient Tissue

Gain better insight into the phenotypic response of your therapeutic candidate in organoids and ex vivo patient tissue.

Learn More

Spatial Multi-Omics Analysis

Certified CRO services with NanoString GeoMx Digital Spatial Profiling.

Learn More

Biomarker Discovery

De-risk your drug development with early identification of candidate biomarkers and utilize our biomarker discovery services to optimize clinical trial design.

Learn More

DMPK Services

Rapidly evaluate your molecule’s pharmaceutical and safety properties with our in vivo drug metabolism and pharmacokinetic (DMPK) services to select the most robust drug formulations.

Learn More

Efficacy Testing

Explore how the novel HuGEMM™ and HuCELL™ platforms can assess the efficacy of your molecule and accelerate your immuno-oncology drug discovery programs.

Learn More

Laboratory Services

Employ cutting-edge multi-omics methods to obtain accurate and comprehensive data for optimal data-based decisions.

Learn More

Pharmacology & Bioanalytical Services

Leverage our suite of structural biology services including, recombinant protein expression and protein crystallography, and target validation services including RNAi.

Learn More

Screens

Find the most appropriate screen to accelerate your drug development: discover in vivo screens with MuScreen™ and in vitro cell line screening with OmniScreen™.

Learn More

Toxicology

Carry out safety pharmacology studies as standalone assessments or embedded within our overall toxicological profiling to assess cardiovascular, metabolic and renal/urinary systems.

Learn More

Our Company

Global CRO in California, USA offering preclinical and translational oncology platforms with high-quality in vivo, in vitro, and ex vivo models.

Learn More

Our Purpose

Learn more about the impact we make through our scientific talent, high-quality standards, and innovation.

Learn More

Our Responsibility

We build a sustainable future by supporting employee growth, fostering leadership, and exceeding customer needs. Our values focus on innovation, social responsibility, and community well-being.

Learn More

Meet Our Leadership Team

We build a sustainable future by fostering leadership, employee growth, and exceeding customer needs with innovation and social responsibility.

Learn More

Scientific Advisory Board

Our Scientific Advisory Board of experts shapes our strategy and ensures top scientific standards in research and development.

Learn More

News & Events

Stay updated with Crown Bioscience's latest news, achievements, and announcements. Check our schedule for upcoming events and plan your visit.

Learn More

Career Opportunities

Join us for a fast-paced career addressing life science needs with innovative technologies. Thrive in a respectful, growth-focused environment.

Learn More

Scientific Publications

Access our latest scientific research and peer-reviewed articles. Discover cutting-edge findings and insights driving innovation and excellence in bioscience.

Learn More

Resources

Discover valuable insights and curated materials to support your R&D efforts. Explore the latest trends, innovations, and expertly curated content in bioscience.

Learn More

Blogs

Explore our blogs for the latest insights, research breakthroughs, and industry trends. Stay educated with expert perspectives and in-depth articles driving innovation in bioscience.

Learn More

  • Platforms
  • Target Solutions
  • Technologies
  • Service Types

Epithelial To Mesenchymal Transition: A Step Back For Cancer Cells, A Step Forward For Drug Discovery

Metastasis remains the main cause of cancer-related mortality, despite major scientific advances in the understanding of the molecular and genetic basis of cancer. The term metastasis refers to the spreading of cancer cells to peripheral tissues, which they colonize after shedding from primary tumors and travelling through the blood stream or lymphatic system. Understanding the mechanisms of metastasis initiation and progression is critical to developing new strategies to treat and prevent metastatic disease.

It is currently believed that cancer cells undergo a de-differentiation process called epithelial-to-mesenchymal transition (EMT) that reverts them into “cancer stem cells” and that EMT cells becomes “seeds” able to initiate and propagate metastatic tumors. However, the identification of these metastasis-initiating cells in human cancer remains a challenge, and only a partial EMT has been occasionally observed in vivo.

Most studies exploring the functional role of EMT in tumors have been developed in cell culture where EMT is artificially induced by loss-of-function and gain-of-function of key EMT inducing factors, whereas in vivo models in which to address a causal connection between EMT, invasion and metastasis are lacking.

Recent findings from two groups investigating the metastatic process in preclinical models of breast and prostate cancer are challenging the dogmatic view that EMT is required for epithelial tumors to metastasize.

The group headed by Dr. Dingcheng Gao at Cornell University, collaborating with teams from Columbia University, Houston Methodist Research Institute, and Soonchunhyang University in South Korea, devised a new approach called “EMT cell lineage tracing" to mark and follow the development of single breast cancer cells in mouse models of metastatic breast cancer. In these engineered models breast cancer cells are labeled with a red fluorescent marker, which turns green if they undergo EMT. Not surprisingly the group found that primary breast tumors contain a small proportion of cells that undergo EMT, however lung metastases mainly consist of non-EMT tumor cells that maintain their original epithelial phenotype.

They also found that lung metastases still develop when EMT is blocked in their models, suggesting that EMT is not required for tumor cells dissemination or peripheral tissues colonization. However EMT becomes key once animals are treated. While primary tumors respond to chemotherapy, cells that have undergone EMT are resistant to treatment and contribute to recurrent lung metastasis formation after chemotherapy. Treating breast cancer bearing animals with an EMT blocker together with standard chemotherapy abrogated this resistance and prevented the formation of metastasis.

These important findings were supported by a back-to-back publication on the same issue of Nature of similar data in a metastatic prostate cancer model, where EMT suppression leads to increase sensitivity to chemotherapy and increased overall survival.

These studies suggest a re-evaluation of the role of EMT in cancer progression. Epithelial cells could enter the bloodstream without transitioning to a mesenchymal state, by alternative means such as collective epithelial-cell migration or tumor fragmentation.

Most importantly they found that the EMT switch could prompt chemo-resistance. By transitioning to a mesenchymal state cancer cells become quiescent and refractory to drugs targeting actively dividing cells. A better understanding of how tumor cells transition to a mesenchymal state and how this process influences drug response is likely to provide fertile ground for drug discovery.

Crown Bioscience has a longstanding track record in prostate and breast cancer research with a range of research platforms available for all stages of drug development. Besides our OmniPanel and ValidatedXenocollections of breast and prostate cancer cell lines, we have developed several cell line derived xenograft (CDX) models, including orthotopic and bioluminescent models for imaging and metastatic disease evaluation.

Crown has also validated a comprehensive collection of PDX breast cancer models (HuPrime®) as well as models for Immunotherapy Research using mouse immunity (syngenic and MuPrime™). Models with human immunity (HuMice) are currently under development.

Contact us today at busdev@crownbio.com for your copy of our Breast Cancer and Prostate cancer Application Notes or for a copy of our factsheet on the mBR6004 MuPrime model of metastatic breast cancer for Immunotherapy research.

 


Related Posts